TDMQ20 as A Drug Candidate for Wilson's Disease: Comparison with D-Penicillamine, Trientine, and Tetrathiomolybdate
Yingshan Zhu1, Weiling Peng1, Guangwei Liu1
1School of Chemical Engineering and Light Industry, Guangdong University of Technology (GDUT), Higher Education Mega Center, Guangzhou 510006, China.
Abstract:
Background/Objectives: The lifelong treatment of Wilson's disease (WD) currently relies on copper chelators with relatively poor metal specificity, which frequently exhibit serious adverse effects. There is a real medical need for a specific copper chelator to regulate the copper excess efficiently, at lower doses than those used for penicillamine (DPA) or trientine (TETA), and with lower toxicity in long-term treatments. Methods: The efficiency of the specific Cu(II) chelator named TDMQ20 was evaluated by oral treatment of TX mice, used as a WD model, and compared with those of DPA, TETA, and also tetrathiomolybdate (bcTTM). We documented TDMQ20's ability to (i) decrease the hepatic copper load, (ii) increase the amount and ferroxidase activity of ceruloplasmin (CP), and (iii) regulate liver proteins that are impaired in WD mice. Results: Compared to the other copper chelators, TDMQ20 was the only one that efficiently mediated excretion of Cu and restoration of active ceruloplasmin levels at doses 8 times lower than DPA. Such efficacy is related to the design of this chelator, which specifically coordinates Cu(II) as a discrete and soluble complex. Conversely, DPA, TETA, and bcTTM give rise to various complexes with copper ions, often with oligomeric or cluster structures that can be retained in blood circulation or sequestered by proteins. Conclusions: Taking into consideration all the advantages of TDMQ20 compared to other ligands, including its lack of toxicity during long-term administration in mice, the drug candidate TDMQ20 appears to be a first-class challenger to the currently used treatments, i.e., DPA, TETA, and bcTTM.
Insights
A novel copper chelator, TDMQ20, shows promise for Wilson's disease (WD) treatment. It effectively reduces copper levels and restores ceruloplasmin with lower doses and toxicity than current therapies.
Area of Science:
- Biochemistry
- Pharmacology
- Toxicology
Background:
- Wilson's disease (WD) requires lifelong copper chelation therapy.
- Current treatments (penicillamine [DPA], trientine [TETA]) have limited specificity and significant adverse effects.
- A need exists for a more specific, safer copper chelator for WD.
Purpose of the Study:
- To evaluate the efficacy and safety of a novel Cu(II) chelator, TDMQ20.
- To compare TDMQ20 with existing WD treatments (DPA, TETA, tetrathiomolybdate [bcTTM]) in a mouse model.
- To assess TDMQ20's impact on hepatic copper, ceruloplasmin, and liver proteins.
Main Methods:
- Oral administration of TDMQ20, DPA, TETA, and bcTTM to TX mice (a WD model).
- Assessment of hepatic copper reduction.
- Measurement of ceruloplasmin (CP) levels and ferroxidase activity.
- Evaluation of liver protein regulation.
Main Results:
- TDMQ20 significantly decreased hepatic copper load and restored active ceruloplasmin levels.
- TDMQ20 was effective at doses 8 times lower than DPA.
- TDMQ20 demonstrated superior copper specificity, forming soluble complexes, unlike DPA, TETA, and bcTTM which formed potentially sequestered complexes.
Conclusions:
- TDMQ20 exhibits high efficacy in reducing copper overload and restoring CP in a WD mouse model.
- TDMQ20 shows a favorable safety profile with no observed toxicity during long-term administration in mice.
- TDMQ20 represents a promising therapeutic candidate for Wilson's disease, potentially superior to current treatments.
More Related Videos
Related Concept Videos
01:26Therapeutic Drug Monitoring: Drug Analysis Methods
01:29Therapeutic Drug Monitoring: Affecting Factors
01:16Therapeutic Drug Monitoring: Overview and Classification